Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mahal

Showing results (131-140 of 210) with videos related to

Pageof 21
Sort By:
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2019
Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast CancersAlexander P Cole, Chang Lu, Marieke J Krimphove, et al.
Advances in Radiation Oncology|April 16, 2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G Zaorsky, James B Yu, Sean M McBride, et al.
Cancer|January 12, 2019
Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?Alexander P Cole, Sean A Fletcher, Sebastian Berg, et al.
Advances in Radiation Oncology|November 4, 2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G Zaorsky, James B Yu, Sean M McBride, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|May 19, 2025
Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United StatesShriya K Garg, Khushi Kohli, Isha K Garg, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
The Journal of Urology|November 12, 2018
Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving HospitalsMarieke J Krimphove, Sean A Fletcher, Alexander P Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2018
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R G Pike, Andrew Bang, Brandon A Mahal, et al.
Pageof 21

Showing results (131-140 of 210) with videos related to

Sort By:
Pageof 21
Urology|September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 6, 2019
Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast CancersAlexander P Cole, Chang Lu, Marieke J Krimphove, et al.
Advances in Radiation Oncology|April 16, 2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G Zaorsky, James B Yu, Sean M McBride, et al.
Cancer|January 12, 2019
Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?Alexander P Cole, Sean A Fletcher, Sebastian Berg, et al.
Advances in Radiation Oncology|November 4, 2020
Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19Nicholas G Zaorsky, James B Yu, Sean M McBride, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|May 19, 2025
Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United StatesShriya K Garg, Khushi Kohli, Isha K Garg, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
The Journal of Urology|November 12, 2018
Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving HospitalsMarieke J Krimphove, Sean A Fletcher, Alexander P Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2018
The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint InhibitorsLuke R G Pike, Andrew Bang, Brandon A Mahal, et al.
Pageof 21